Daiichi Sankyo

Japanese pharmaceutical giant leading in antibody-drug conjugates (ADCs)

Company Overview

Daiichi Sankyo is one of Japan's largest pharmaceutical companies and a global leader in antibody-drug conjugate (ADC) technology. The company's partnership with AstraZeneca on Enhertu has produced one of the most successful cancer drugs in recent history. Daiichi Sankyo's ADC pipeline represents a new paradigm in targeted cancer therapy.

Sectors

PharmaceuticalsOncologyADC Technology

Primary Markets

JapanGlobal

Why This Company Matters

Daiichi Sankyo's ADC platform has established Japan as a global leader in next-generation cancer therapeutics, with a pipeline valued at tens of billions of dollars.

Key Focus Areas

Antibody-Drug ConjugatesOncologyRare DiseasesVaccines

Peer Companies

View all

BeiGene

1 signals

China's largest global biotech company focused on innovative oncology medicines

Beijing, China

Biocon

1 signals

India's largest biopharmaceutical company and global biosimilars leader

Bangalore, India

Celltrion

0 signals

South Korea's leading biosimilar manufacturer challenging global pharma giants

Incheon, South Korea

Doctor Anywhere

0 signals

Southeast Asia's leading omnichannel healthcare platform

Singapore

Halodoc

1 signals

Indonesia's leading telehealth and health-tech platform

Jakarta, Indonesia

Healius

0 signals

Australia's second-largest private pathology and imaging provider

Sydney, Australia

Signal Timeline

0 total

No signals tracked yet for this company.

Signals will appear here as official announcements are indexed.

We are actively monitoring this company's official channels. Signals will appear as they are discovered.

Get Daiichi Sankyo signal updates

Get notified when new signals are published for this company.